enGene ramps R&D for detalimogene; $225M liquidity but rising burn, debt and governance risks

Quick take - enGene Holdings Inc. (NASDAQ: ENGNW)
Clinical‑stage biotech advancing its lead candidate detalimogene in the Phase 1/2 LEGEND program and preparing a planned BLA filing in 2H 2026. Financials show a deliberate ramp in R&D and headcount, funded by cash + marketable securities, a term loan facility and prior PIPE capital - but burn has accelerated and governance weaknesses remain.

Key facts & statistics (as reported; amounts in thousands of USD)
* Cash and cash equivalents: $32,623 (July 31, 2025)
* Marketable securities - short term: $169,290; long term: $23,011 (July 31, 2025)
* Total current assets: $211,312; Total assets: $245,550 (July 31, 2025)
* Total current liabilities: $20,440; Total liabilities: $44,878 (July 31, 2025)
* Shareholders' equity: $200,672 (July 31, 2025) - down from $272,612 at Oct 31, 2024
* Common shares outstanding: 51,105,807 (July 31, 2025); weighted‑average shares (Q3): 51,097,711
* Warrants outstanding: 8,511,968; Options outstanding: 9,408,647; ESPP reserved: 2,000,000
* Net loss - three months ended July 31, 2025: $28,991; (three months ended July 31, 2024: $14,148)
* Net loss - nine months ended July 31, 2025: $79,422; (nine months ended July 31, 2024: $39,843)
* Net loss per share (basic & diluted): $0.57 (quarter) and $1.56 (nine months) for 2025
* R&D expense - three months: $22,575 (2025) vs $11,549 (2024); nine months: $62,758 (2025) vs $27,042 (2024)
* G&A expense - three months: $7,372 (2025) vs $5,210 (2024); nine months: $20,926 (2025) vs $17,800 (2024)
* Cash used in operating activities (nine months): $(74,277) (2025) vs $(28,713) (2024)
* Note payable (net of current portion): $17,706 current portion $5,412; note payable, net of discount: $23,118 (July 31, 2025)
* Marketable securities purchases (nine months): $153,095; maturities proceeds: $88,505 (nine months ended July 31, 2025)

What's happening inside the company
* Clinical push: Significant ramp of spending on detalimogene to advance LEGEND (pivotal cohort) and to support a planned BLA filing in 2H 2026 - direct detalimogene spend rose materially (see R&D numbers).
* Hiring and commercial prep: Increased personnel and inducement option grants to build clinical, quality, medical affairs and commercial capabilities (share‑based comp and personnel costs up).
* Real estate expansion: New 26,335 sq ft Boston lease commenced June 2025; right‑of‑use asset recognized (~$6.5M) and lease liabilities increased - indicates scaling US footprint.
* Financing posture: Drew $22.5M under Hercules Term Loan (effective rate ~11.63%); $27.5M of the facility remains undrawn (subject to lender approval). Open Market Sale Agreement with Jefferies for up to $100M remains available but unused as of July 31, 2025. Prior PIPE (Feb 2024) provided $200M.
* Equity dilution potential: Large pool of warrants and options outstanding (8.5M warrants; 9.4M options), plus evergreen equity plan and newly approved ESPP (2.0M).
* Controls & governance: Management disclosed three remaining material weaknesses in internal controls (IT controls; segregation of duties; formal policies) and is actively remediating.

Income statement - positives
* Spending is mission‑aligned - rising R&D ($62,758 YTD) reflects active clinical development and preparation for regulatory filings, which is what investors expect from a clinical‑stage biotech.
* General and administrative increases are mainly personnel investments needed to scale toward commercialization.
* Interest income and sizeable marketable securities (total fair value $208,124) provide liquidity buffer and some interest offset to operating burn.
* Company reports cash, cash equivalents and marketable securities of ~$224.9M and states this is sufficient to fund operations and debt obligations for at least the next 12 months from issuance of the financials.

Income statement - negatives / risks
* Loss escalation: Quarterly net loss doubled year‑over‑year to $28,991 and nine‑month net loss nearly doubled to $79,422 - operating expenses increased sharply (total operating expenses $83,684 YTD).
* High cash burn: Operating cash used $(74,277) in nine months - runway depends on preserving marketable securities and accessing undrawn debt/trading facility.
* Leverage & near‑term debt: Current portion of note payable $5,412 and total principal payments scheduled (including end‑of‑term charges) of ~$24,565 total - interest and PIK interest increase financing costs.
* Dilution risk: Large outstanding options/warrants (combined potential supply >17M shares) could dilute shareholders if exercised; weighted‑average shares already increased vs prior period.
* Governance weakness: Remaining material weaknesses in internal control increase execution and reporting risk until remediated.
* Accumulated deficit: $334,152 and no product revenue - company must raise additional capital to progress beyond current plans if timelines slip or costs exceed forecasts.

Near‑term catalysts & watch points
* LEGEND trial milestones and enrollment updates - directly drive future valuation and ability to file BLA (planned 2H 2026).
* Cash burn vs. reported runway - monitor quarterly cash, marketable securities and any drawdown of the $27.5M Hercules tranche or sales under Jefferies agreement.
* Progress on remediation of internal control material weaknesses and any related auditor commentary.
* Any equity or debt raises (timing, size, pricing) will materially affect dilution and financing costs.

Bottom line
enGene (NASDAQ: ENGNW) is clearly investing to advance detalimogene toward a pivotal data set and a planned BLA. That activity is visible in the income statement (sharp R&D increase) and in hiring/leases. The company has meaningful liquidity today (~$224.9M in cash + securities) and financing options available, but cash burn is high, losses are growing, debt costs and dilution risk are real, and remedial work on internal controls remains incomplete. Investors should watch clinical readouts, cash runway updates, and any financing moves closely.